IDEXX Laboratories (IDXX)
(Delayed Data from NSDQ)
$476.27 USD
+2.99 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $476.27 0.00 (0.00%) 6:34 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$476.27 USD
+2.99 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $476.27 0.00 (0.00%) 6:34 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
Zacks News
BD's (BDX) New Offering to Boost Labs' Flow Cytometry Abilities
by Zacks Equity Research
BD's (BDX) latest product offering is expected to help improve access to instrumentation for complex scientific research to more laboratories.
3 Reasons Why Growth Investors Shouldn't Overlook Idexx (IDXX)
by Zacks Equity Research
Idexx (IDXX) possesses solid growth attributes, which could help it handily outperform the market.
Amedisys (AMED) Suffers From Low Occupancy Amid Pandemic
by Zacks Equity Research
The prolonged and lingering impact of COVID-19 on Amedisys (AMED) Hospice business has hampered its ability to grow at the earlier-projected rates.
Thermo Fisher (TMO) Hits a 52-Week High: What's Driving It?
by Zacks Equity Research
Strong performance by the four reported business segments is driving the top line for Thermo Fisher (TMO).
Here's Why You Should Add Henry Schein (HSIC) to Your Portfolio
by Zacks Equity Research
Strong performance by the Dental, Medical & Technology and Value-Added Services segments is driving Henry Schein's (HSIC) top line.
Is IDEXX Laboratories (IDXX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (IDXX) Outperforming Other Medical Stocks This Year?
3 Medical Instruments Stocks Countering Industry Headwinds
by Urmimala Biswas
The Zacks Medical - Instruments industry is growing on base business recovery. ISRG, IDXX and ALC are set to gain the most. However, falling demand for COVID-19 tests might disrupt the trend.
IDEXX (IDXX) Q2 Earnings Beat Estimates, 2021 Guidance Up
by Zacks Equity Research
Strength in CAG Diagnostics and Water businesses drove IDEXX's (IDXX) second-quarter revenues.
Idexx Laboratories (IDXX) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 16.42% and 5.72%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Why IDEXX Laboratories (IDXX) Might Surprise This Earnings Season
by Zacks Equity Research
IDEXX Laboratories (IDXX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Should JPMorgan Diversified Return U.S. Mid Cap Equity ETF (JPME) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JPME
What's in Store for IDEXX Laboratories (IDXX) in Q2 Earnings?
by Zacks Equity Research
IDEXX's (IDXX) fiscal second-quarter top line is expected to have benefited from strength in CAG and LPD businesses.
Idexx Laboratories (IDXX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Idexx (IDXX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Idexx (IDXX) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Idexx (IDXX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's How Much a $1000 Investment in Idexx Laboratories Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Here's Why You Should Add Teleflex (TFX) to Your Portfolio
by Zacks Equity Research
Strong segmental performance in America and Asia is driving the top line for Teleflex (TFX).
IDEXX Laboratories (IDXX) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Strong sales at the CAG and LPD arms are driving the top line for IDEXX Laboratories (IDXX).
Abbott's (ABT) DAPT for High Bleeding Risk Gets FDA Approval
by Zacks Equity Research
Abbott's (ABT) DAPT can be discontinued safely early as short as 28 days with no higher risk in patient adverse events.
LabCorp (LH) Expands Testing Portfolio With the Launch of CDx
by Zacks Equity Research
LabCorp's (LH) new test expands the company's leadership in bringing testing solutions for new precision medicines used to treat patients with lung cancer.
Myriad Genetics (MYGN) Divests Myriad RBM to Focus on Core Units
by Zacks Equity Research
Myriad Genetics' (MYGN) new divesture will enable company to accelerate the execution of transformation plan and drive growth.
Orthofix (OFIX) Launches FORZA Ti PLIF Spacer System in the US
by Zacks Equity Research
Orthofix (OFIX) launches FORZA Ti PLIF Spacer System to improve posterior lumbar interbody fusion procedures in the United States.
QIAGEN (QGEN) & Verogen Team Up to Employ NGS-Based Forensics
by Zacks Equity Research
QIAGEN's (QGEN) new collaboration will offer customers advanced tools and comprehensive support for HID workflows in laboratories.
Pandemic Boosts Animal Health Spending: 4 Stocks to Buy
by Riya Anand
Stocks like PetIQ (PETQ), IDEXX Laboratories (IDXX), Phibro Animal Health (PAHC) and Zoetis (ZTS) offering animal health products and services make great picks for long term.
Globus Medical (GMED) Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Globus Medical (GMED) owing to significant trend improvement and the company's focus on product development.
Penumbra (PEN) Gets FDA Nod for RED 62, Grows Thrombectomy Line
by Zacks Equity Research
Penumbra (PEN) to initiate commercialization of RED 62 Reperfusion Catheter post FDA clearance.